These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

534 related articles for article (PubMed ID: 22177546)

  • 1. Changes in MIC within a global collection of Acinetobacter baumannii collected as part of the Tigecycline Evaluation and Surveillance Trial, 2004 to 2009.
    Morfin-Otero R; Dowzicky MJ
    Clin Ther; 2012 Jan; 34(1):101-12. PubMed ID: 22177546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antimicrobial susceptibility among gram-negative isolates collected from intensive care units in North America, Europe, the Asia-Pacific Rim, Latin America, the Middle East, and Africa between 2004 and 2009 as part of the Tigecycline Evaluation and Surveillance Trial.
    Bertrand X; Dowzicky MJ
    Clin Ther; 2012 Jan; 34(1):124-37. PubMed ID: 22154196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of tigecycline and comparators on Acinetobacter spp. isolates collected from patients with bacteremia and MIC change during the Tigecycline Evaluation and Surveillance Trial, 2004 to 2008.
    Wang YF; Dowzicky MJ
    Diagn Microbiol Infect Dis; 2010 Sep; 68(1):73-9. PubMed ID: 20727474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High tigecycline resistance in multidrug-resistant Acinetobacter baumannii.
    Navon-Venezia S; Leavitt A; Carmeli Y
    J Antimicrob Chemother; 2007 Apr; 59(4):772-4. PubMed ID: 17353223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In-vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii in Taiwan.
    Liu JW; Wang LS; Cheng YJ; Hsu GJ; Lu PL; Liu YC; Chen CM; Lee CM; Sun W; Jang TN; Chiang PC; Chuang YC; Lin HC; Shi ZY; Kung HC; Huang CH; Tsao SM; Lu CT; Liao CH; Hsueh PR
    Int J Antimicrob Agents; 2008 Nov; 32 Suppl 3():S188-91. PubMed ID: 19013353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on antimicrobial susceptibility rates among gram-negative and gram-positive organisms in the United States: results from the Tigecycline Evaluation and Surveillance Trial (TEST) 2005 to 2007.
    Dowzicky MJ; Park CH
    Clin Ther; 2008 Nov; 30(11):2040-50. PubMed ID: 19108792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units.
    Timurkaynak F; Can F; Azap OK; Demirbilek M; Arslan H; Karaman SO
    Int J Antimicrob Agents; 2006 Mar; 27(3):224-8. PubMed ID: 16464562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Susceptibility to tigecycline and linezolid among gram-positive isolates collected in the United States as part of the tigecycline evaluation and surveillance trial (TEST) between 2004 and 2009.
    Dowzicky MJ
    Clin Ther; 2011 Dec; 33(12):1964-73. PubMed ID: 22078154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimicrobial susceptibility among Acinetobacter calcoaceticus-baumannii complex and Enterobacteriaceae collected as part of the Tigecycline Evaluation and Surveillance Trial.
    Halstead DC; Abid J; Dowzicky MJ
    J Infect; 2007 Jul; 55(1):49-57. PubMed ID: 17250897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of tigecycline in the control of a carbapenem-resistant Acinetobacter baumannii outbreak in an intensive care unit.
    Jamal W; Salama M; Dehrab N; Al Hashem G; Shahin M; Rotimi VO
    J Hosp Infect; 2009 Jul; 72(3):234-42. PubMed ID: 19493588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimicrobial susceptibility among organisms from the Asia/Pacific Rim, Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecycline.
    Reinert RR; Low DE; Rossi F; Zhang X; Wattal C; Dowzicky MJ
    J Antimicrob Chemother; 2007 Nov; 60(5):1018-29. PubMed ID: 17855724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of tigecycline and comparators against Gram-positive and Gram-negative isolates collected from the Middle East and Africa between 2004 and 2011.
    Kanj SS; Whitelaw A; Dowzicky MJ
    Int J Antimicrob Agents; 2014 Feb; 43(2):170-8. PubMed ID: 24315313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of tigecycline as a therapeutic option against multidrug-resistant Acinetobacter spp.
    Eser OK; Ergin A; Tunçkanat F; Hasçelik G
    New Microbiol; 2008 Oct; 31(4):535-42. PubMed ID: 19123310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004-2007).
    Nørskov-Lauritsen N; Marchandin H; Dowzicky MJ
    Int J Antimicrob Agents; 2009 Aug; 34(2):121-30. PubMed ID: 19342205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of tigecycline against clinical isolates of multidrug-resistant Acinetobacter baumannii in Siriraj Hospital, Thailand.
    Tiengrim S; Tribuddharat C; Thamlikitkul V
    J Med Assoc Thai; 2006 Nov; 89 Suppl 5():S102-5. PubMed ID: 17718251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of tigecycline and comparators against skin and skin structure pathogens: global results of the Tigecycline evaluation and surveillance trial, 2004-2009.
    Namdari H; Tan TY; Dowzicky MJ
    Int J Infect Dis; 2012 Jan; 16(1):e60-6. PubMed ID: 22104303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimicrobial susceptibility of extended-spectrum beta-lactamase producers and multidrug-resistant Acinetobacter baumannii throughout the United States and comparative in vitro activity of tigecycline, a new glycylcycline antimicrobial.
    Hoban DJ; Bouchillon SK; Dowzicky MJ
    Diagn Microbiol Infect Dis; 2007 Apr; 57(4):423-8. PubMed ID: 17403448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimicrobial susceptibility of gram-negative and gram-positive bacteria collected from countries in Eastern Europe: results from the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) 2004-2010.
    Balode A; Punda-Polić V; Dowzicky MJ
    Int J Antimicrob Agents; 2013 Jun; 41(6):527-35. PubMed ID: 23590898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clonal spread of multidrug-resistant Acinetobacter baumannii in eastern Taiwan.
    Chang KC; Lin MF; Lin NT; Wu WJ; Kuo HY; Lin TY; Yang TL; Chen YC; Liou ML
    J Microbiol Immunol Infect; 2012 Feb; 45(1):37-42. PubMed ID: 22154678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive assessment of tigecycline activity tested against a worldwide collection of Acinetobacter spp. (2005-2009).
    Mendes RE; Farrell DJ; Sader HS; Jones RN
    Diagn Microbiol Infect Dis; 2010 Nov; 68(3):307-11. PubMed ID: 20955916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.